

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 DEC 01 ChemPort single article sales feature unavailable  
NEWS 3 JAN 06 The retention policy for unread STNmail messages  
will change in 2009 for STN-Columbus and STN-Tokyo  
NEWS 4 JAN 07 WPIDS, WPINDEX, and WPIX enhanced Japanese Patent  
Classification Data  
NEWS 5 FEB 02 Simultaneous left and right truncation (SLART) added  
for CERAB, COMPUAB, ELCOM, and SOLIDSTATE  
NEWS 6 FEB 02 GENBANK enhanced with SET PLURALS and SET SPELLING  
NEWS 7 FEB 06 Patent sequence location (PSL) data added to USGENE  
NEWS 8 FEB 10 COMPENDEX reloaded and enhanced  
NEWS 9 FEB 11 WTEXTILES reloaded and enhanced  
NEWS 10 FEB 19 New patent-examiner citations in 300,000 CA/CAPLUS  
patent records provide insights into related prior  
art  
NEWS 11 FEB 19 Increase the precision of your patent queries -- use  
terms from the IPC Thesaurus, Version 2009.01  
NEWS 12 FEB 23 Several formats for image display and print options  
discontinued in USPATFULL and USPAT2  
NEWS 13 FEB 23 MEDLINE now offers more precise author group fields  
and 2009 MeSH terms  
NEWS 14 FEB 23 TOXCENTER updates mirror those of MEDLINE - more  
precise author group fields and 2009 MeSH terms  
NEWS 15 FEB 23 Three million new patent records blast AEROSPACE into  
STN patent clusters  
NEWS 16 FEB 25 USGENE enhanced with patent family and legal status  
display data from INPADOCDB  
NEWS 17 MAR 06 INPADOCDB and INPAFAMDB enhanced with new display  
formats  
NEWS 18 MAR 11 EPFULL backfile enhanced with additional full-text  
applications and grants  
NEWS 19 MAR 11 ESBIOBASE reloaded and enhanced  
NEWS 20 MAR 20 CAS databases on STN enhanced with new super role  
for nanomaterial substances  
NEWS 21 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent  
equivalents from China  
NEWS 22 MAR 30 IMSPATENTS reloaded and enhanced  
NEWS 23 APR 03 CAS coverage of exemplified prophetic substances  
enhanced  
NEWS 24 APR 07 STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 14:19:07 ON 17 APR 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 14:19:30 ON 17 APR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9  
DICTIONARY FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10597283.str



```

chain nodes :
10
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
1-10 4-7 5-9 7-8 8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :
```


G1:C,N

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
```

L1 STRUCTURE UPLOADED

=> d l1  
L1 HAS NO ANSWERS  
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full  
FULL SEARCH INITIATED 14:19:48 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 67132 TO ITERATE

100.0% PROCESSED 67132 ITERATIONS 606 ANSWERS  
SEARCH TIME: 00.00.02

L2 606 SEA SSS FUL L1

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	185.88	186.10

FILE 'CAPLUS' ENTERED AT 14:19:54 ON 17 APR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2009 VOL 150 ISS 17  
FILE LAST UPDATED: 16 Apr 2009 (20090416/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 12 full  
L3 86 L2

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.50	186.60

FILE 'REGISTRY' ENTERED AT 14:20:03 ON 17 APR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9  
DICTIONARY FILE UPDATES: 15 APR 2009 HIGHEST RN 1135193-69-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10597283a.str



chain nodes :

13 14

ring nodes :

1 2 3 4 5 6 7 8 9 16 17 18 19 20

chain bonds :

1-16 2-14 3-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 16-17 16-20 17-18 18-19 19-20

exact/norm bonds :

1-16 2-14 3-13 4-7 5-9 7-8 8-9 16-17 16-20 17-18 18-19 19-20

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 16 :

G1:C,N

G2:H,CH3,Et

G3:C,O,S,N

G4:O,N

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 13:CLASS  
14:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom

L4 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS

L4 STR



G1 C,N

G2 H, Me, Et

G3 C,O,S,N

G4 O,N

Structure attributes must be viewed using STN Express query preparation.

=> s 14 full

FULL SEARCH INITIATED 14:23:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1005 TO ITERATE

100.0% PROCESSED 1005 ITERATIONS

206 ANSWERS

SEARCH TIME: 00.00.01

L5 206 SEA SSS FUL L4

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

188.76

375.36

FILE 'CAPLUS' ENTERED AT 14:24:00 ON 17 APR 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Apr 2009 VOL 150 ISS 17  
FILE LAST UPDATED: 16 Apr 2009 (20090416/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 15 full

L6                    4 L5

=> d ibib abs hitstr tot



L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1450617 CAPLUS

DOCUMENT NUMBER: 150:5766

TITLE: Derivatives of triazolopyridine carboxamides, particularly (piperazin-1-yl)(1,2,3-triazolo[4,5-b]pyridin-1-yl)methanones, their preparation and use as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors

INVENTOR(S): Even, Luc; Hoornaert, Christian

PATENT ASSIGNEE(S): Sanofi-Aventis, Fr.

SOURCE: PCT Int. Appl., 27pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008145843	A1	20081204	WO 2008-FR536	20080416
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

FR 2915198	A1	20081024	FR 2007-2808	20070418
------------	----	----------	--------------	----------

PRIORITY APPLN. INFO.:	FR 2007-2808	A	20070418
------------------------	--------------	---	----------

OTHER SOURCE(S): MARPAT 150:5766

GI




II

AB Title compds. I [X = H, halo, alkyl, alkoxy, OH, etc.; A = absent, a bond, O, S, NH and derivs., CONH and derivs., SO<sub>2</sub>NH and derivs., alk(en)ylene; R<sub>1</sub>, R<sub>2</sub> = independently H, alkyl, CN, halo, etc.; their free bases, acid addition salts, hydrates and solvates] were prepared as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors for treating MGL- and FAAH-related pathologies. Thus, amidation of 4-(3-trifluoromethylphenyl)-1-piperazinecarbonyl chloride with 2-amino-6-chloro-3-nitropyridine, coupling of the chloride with 4-chlorophenylboronic acid, reduction of the nitro intermediate and diazotization/cyclization of the amine gave triazolopyridine carboxamide II. In a radioenzymic test measuring the in vitro inhibitory activity of I towards MGL, II inhibited MGL with IC<sub>50</sub> = 0.002 µM. In a radioenzymic test measuring the in vitro inhibitory activity of I towards FAAH, II inhibited FAAH with IC<sub>50</sub> = 0.002 µM. I are useful for treating and preventing pathologies in which endogenous 2-arachidonoylglycerol and 1(3)-arachidonoylglycerol and/or other substrate metabolized by MLG and/or in which endogenous anandamide and/or other substrate metabolized by FAAH are implied.

IT 1072874-85-1P, [5-(Furan-3-yl)-[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of triazolopyridine carboxamides as selective monoacyl glycerol lipase or mixed monoacyl glycerol lipase and fatty acid amide hydrolase inhibitors)

RN 1072874-85-1 CAPLUS

CN Methanone, [5-(3-furanyl)-3H-1,2,3-triazolo[4,5-b]pyridin-3-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1279746 CAPLUS

DOCUMENT NUMBER: 149:493691

TITLE: Derivatives of triazolopyridine carboxamides, particularly (piperazin-1-yl)(1,2,3-triazolo[4,5-b]pyridin-1-yl)methanones, their preparation and use as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors

INVENTOR(S): Even, Luc; Hoornaert, Christian

PATENT ASSIGNEE(S): Sanofi Aventis, Fr.

SOURCE: Fr. Demande, 22pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2915198	A1	20081024	FR 2007-2808	20070418
WO 2008145843	A1	20081204	WO 2008-FR536	20080416
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: FR 2007-2808 A 20070418

OTHER SOURCE(S): MARPAT 149:493691

GI



AB Title compds. I [X = H, halo, alkyl, alkoxy, OH, etc.; A = absent, a bond, O, S, NH and derivs., CONH and derivs., SO<sub>2</sub>NH and derivs., alk(en)ylene; R<sub>1</sub>, R<sub>2</sub> = independently H, alkyl, CN, halo, etc.; their free bases, acid addition salts, hydrates and solvates] were prepared as selective monoacyl glycerol lipase (MGL) inhibitors or mixed MGL and fatty acid amide hydrolase inhibitors for treating MGL- and FAAH-related pathologies. Thus, amidation of 4-(3-trifluoromethylphenyl)-1-piperazinecarbonyl chloride with 2-amino-6-chloro-3-nitropyridine, coupling of the chloride with 4-chlorophenylboronic acid, reduction of the nitro intermediate and diazotization/cyclization of the amine gave triazolopyridine carboxamide II. In a radioenzymic test measuring the in vitro inhibitory activity of I towards MGL, II inhibited MGL with IC<sub>50</sub> = 0.002 μM. In a radioenzymic test measuring the in vitro inhibitory activity of I towards FAAH, II inhibited FAAH with IC<sub>50</sub> = 0.002 μM. I are useful for treating and preventing pathologies in which endogenous 2-arachidonoylglycerol and 1(3)-arachidonoylglycerol and/or other substrate metabolized by MLG and/or in which endogenous anandamide and/or other substrate metabolized by FAAH are implied.


IT 1072874-85-1P, [5-(Furan-3-yl)-[1,2,3]triazolo[4,5-b]pyridin-3-yl][4-(3-trifluoromethylphenyl)piperazin-1-yl]methanone

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of triazolopyridine carboxamides as selective monoacyl glycerol lipase or mixed monoacyl glycerol lipase and fatty acid amide hydrolase inhibitors)

RN 1072874-85-1 CAPLUS

CN Methanone, [5-(3-furanyl)-3H-1,2,3-triazolo[4,5-b]pyridin-3-yl][4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2008:26083 CAPLUS  
 DOCUMENT NUMBER: 148:205319  
 TITLE: Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines  
 as potent p38 $\alpha$  MAP kinase inhibitors with  
 excellent in vivo antiinflammatory properties  
 AUTHOR(S): Mader, Mary; de Dios, Alfonso; Shih, Chuan;  
 Bonjouklian, Rosanne; Li, Tiechao; White, Wesley;  
 Lopez de Uralde, Beatriz; Sanchez-Martinez,  
 Concepcion; del Prado, Miriam; Jaramillo, Carlos; de  
 Diego, Eugenio; Martin Cabrejas, Luisa M.; Dominguez,  
 Carmen; Montero, Carlos; Shepherd, Timothy; Dally,  
 Robert; Toth, John E.; Chatterjee, Arindam; Pleite,  
 Sehila; Blanco-Urgoiti, Jaime; Perez, Leticia;  
 Barberis, Mario; Lorite, Maria Jose; Jambrina,  
 Enrique; Nevill, C. Richard; Lee, Paul A.; Schultz,  
 Richard C.; Wolos, Jeffrey A.; Li, Li C.; Campbell,  
 Robert M.; Anderson, Bryan D.  
 CORPORATE SOURCE: Centro de Investigacion, Lilly S.A., Eli Lilly and  
 Co., Madrid, 28108, Spain  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2008),  
 18(1), 179-183  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 148:205319

AB Herein we report investigations into the p38 $\alpha$  MAP kinase activity of  
 trisubstituted imidazoles that led to the identification of compds.  
 possessing highly potent in vivo activity. The SAR of a novel series of  
 imidazopyridines is demonstrated as well, resulting in compds. possessing  
 cellular potency and enhanced in vivo activity in the rat collagen-induced  
 arthritis model of chronic inflammation.


IT 862504-79-8P 862504-97-0P 862505-00-8P  
 862505-05-3P 862505-19-9P 862505-22-4P  
 862505-50-8P 862505-55-3P 862505-60-0P  
 862505-94-0P 862505-99-5P 862506-00-1P  
 862506-16-9P 862507-23-1P 1005349-47-2P  
 1005349-48-3P 1005349-49-4P 1005349-52-9P  
 1005349-53-0P 1005349-54-1P 1005349-55-2P  
 1005349-56-3P 1005349-57-4P 1005349-58-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(imidazolyl benzimidazoles and imidazopyridines as p38 $\alpha$  MAP  
 kinase inhibitors with antiinflammatory properties)

RN 862504-79-8 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-  
 imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 862504-97-0 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-(4-

fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-00-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-05-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-19-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-22-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-50-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 862505-55-3 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 862505-60-0 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)






RN 862505-94-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 862505-99-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862506-00-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-99-5


CMF C23 H28 N6



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 862506-16-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862507-23-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-00-8


CMF C24 H29 F N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 1005349-47-2 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 862505-50-8  
CMF C25 H22 F2 N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 1005349-48-3 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 862505-94-0  
CMF C25 H21 F2 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 1005349-49-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 862504-79-8


CMF C26 H24 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 1005349-52-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 862505-55-3


CMF C25 H22 Cl2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 1005349-53-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 862505-60-0


CMF C25 H20 Cl2 F2 N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 1005349-54-1 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 862506-16-9  
 CMF C23 H26 F2 N6



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 1005349-55-2 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 862505-22-4  
 CMF C26 H24 Cl F N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 1005349-56-3 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)


CM 1

CRN 862504-97-0  
CMF C26 H23 F3 N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 1005349-57-4 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 862505-19-9  
CMF C26 H23 Cl2 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 1005349-58-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 862505-05-3

CMF C24 H28 F2 N6




CM 2


CRN 75-75-2

CMF C H4 O3 S






IT 1005349-46-1  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (imidazolyl benzimidazoles and imidazopyridines as p38 $\alpha$  MAP  
 kinase inhibitors with antiinflammatory properties)  
 RN 1005349-46-1 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-  
 imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:1) (CA  
 INDEX NAME)  
 CM 1  
 CRN 862506-70-5  
 CMF C24 H20 F2 N6 O2 S



CM 2  
 CRN 75-75-2  
 CMF C H4 O3 S



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:823708 CAPLUS  
DOCUMENT NUMBER: 143:229855  
TITLE: Preparation of imidazo-pyridine derivatives as p38  
kinase inhibitors  
INVENTOR(S): Bonjouklian, Rosanne; Hamdouchi, Chafiq Hamdouchi;  
Shih, Chuan; De Dios, Alfonso; Del Prado, Miriam  
Filadelfa; Jaramillo Aguado, Carlos; Kotiyan, Pramila;  
Mader, Mary Margaret; Selgas, Sheila Pleite;  
Sanchez-Martinez, Concepcion  
PATENT ASSIGNEE(S): Eli Lilly and Company, USA  
SOURCE: PCT Int. Appl., 76 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2005075478	A1	20050818	WO 2005-US25	20050125
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005210459	A1	20050818	AU 2005-210459	20050125
CA 2559128	A1	20050818	CA 2005-2559128	20050125
EP 1713805	A1	20061025	EP 2005-704878	20050125
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1938302	A	20070328	CN 2005-80010142	20050125
RU 2348635	C2	20090310	RU 2006-138606	20050125
US 20090036445	A1	20090205	US 2006-597283	20060719
IN 2006MN01085	A	20070420	IN 2006-MN1085	20060911
PRIORITY APPLN. INFO.:			US 2004-540830P	P 20040130
			WO 2005-US25	W 20050125
OTHER SOURCE(S):			CASREACT 143:229855; MARPAT 143:229855	
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [X = N or CR1; R = alkyl, cycloalkyl, alkylene, etc.; R1 = H, amino, Me, etc.; W = (un)substituted imidazole, pyrazole, oxazole, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of p38 kinase. Thus, e.g., II was prepared by substitutions of 2,6-dichloro-3-nitropyridine with neopentylamine and phenylacetylene followed by oxidation and cyclization with trimethylacetaldehyde to give III. III was then reduced and subsequently treated with cyanogen bromide to yield free base II, which was then converted into the methanesulfonate salt using methanesulfonic acid. The inhibitory activity of I towards p38 kinase was evaluated in scintillation assays and it was revealed that selected compds. of the invention


displayed IC50 values in the range of 2.3 up to 7.2 nM. I as inhibitor of p38 kinase should prove useful in the treatment of multiple myeloma. Pharmaceutical compns. comprising I are disclosed.

IT 862504-88-9P 862505-00-8P 862505-05-3P  
862505-07-5P 862505-10-0P 862505-19-9P  
862505-22-4P 862505-72-4P 862505-90-6P  
862505-97-3P 862506-30-7P 862506-50-1P  
862506-60-3P 862506-70-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of imidazo-pyridine derivs. as inhibitors of p38 kinase)


RN 862504-88-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2,2-dimethylpropyl)-5-[4-(4-fluorophenyl)-2-[2-fluoro-6-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-  
(CA INDEX NAME)




RN 862505-00-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 862505-05-3 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)



RN 862505-07-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 862505-10-0 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 862505-19-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-22-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-72-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl- (CA INDEX NAME)




RN 862505-90-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)- (CA INDEX NAME)




RN 862505-97-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-pyrazol-4-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862506-30-7 CAPLUS

CN Methanimidamide, N'-[5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-3H-imidazo[4,5-b]pyridin-2-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 862506-50-1 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 862506-60-3 CAPLUS


CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide, 2-amino-5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)



RN 862506-70-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-

imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]- (CA INDEX NAME)



IT 862504-77-6P 862504-80-1P 862504-83-4P  
 862504-86-7P 862504-89-0P 862504-92-5P  
 862504-95-8P 862504-98-1P 862505-01-9P  
 862505-03-1P 862505-06-4P 862505-08-6P  
 862505-11-1P 862505-14-4P 862505-16-6P  
 862505-18-8P 862505-20-2P 862505-23-5P  
 862505-26-8P 862505-28-0P 862505-30-4P  
 862505-32-6P 862505-35-9P 862505-37-1P  
 862505-39-3P 862505-41-7P 862505-44-0P  
 862505-47-3P 862505-49-5P 862505-51-9P  
 862505-54-2P 862505-56-4P 862505-59-7P  
 862505-61-1P 862505-63-3P 862505-67-7P  
 862505-70-2P 862505-73-5P 862505-76-8P  
 862505-79-1P 862505-82-6P 862505-84-8P  
 862505-87-1P 862505-89-3P 862505-91-7P  
 862505-93-9P 862505-95-1P 862505-98-4P  
 862506-00-1P 862506-03-4P 862506-05-6P  
 862506-07-8P 862506-09-0P 862506-12-5P  
 862506-15-8P 862506-17-0P 862506-19-2P  
 862506-21-6P 862506-23-8P 862506-26-1P  
 862506-28-3P 862506-31-8P 862506-33-0P  
 862506-35-2P 862506-37-4P 862506-40-9P  
 862506-43-2P 862506-46-5P 862506-49-8P  
 862506-51-2P 862506-54-5P 862506-56-7P  
 862506-59-0P 862506-61-4P 862506-64-7P  
 862506-66-9P 862506-68-1P 862506-71-6P  
 862506-73-8P 862506-76-1P 862506-79-4P  
 862506-81-8P 862506-84-1P 862506-85-2P  
 862506-88-5P 862506-91-0P 862506-94-3P  
 862506-97-6P 862506-99-8P 862507-01-5P  
 862507-04-8P 862507-07-1P 862507-10-6P  
 862507-13-9P 862507-15-1P 862507-18-4P  
 862507-22-0P 862507-23-1P 862507-25-3P  
 862507-27-5P 862507-29-7P 862535-99-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of imidazo-pyridine derivs. as inhibitors of p38 kinase)


RN 862504-77-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-  
 imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX  
 NAME)

CM 1

CRN 862504-76-5


CMF C24 H30 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862504-80-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862504-79-8


CMF C26 H24 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 862504-83-4 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)



CM 1

CRN 862504-82-3


CMF C23 H26 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862504-86-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-(2-cyclopropyl-4-phenyl-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862504-85-6


CMF C23 H26 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862504-89-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2,2-dimethylpropyl)-5-[4-(4-fluorophenyl)-2-[2-fluoro-6-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862504-88-9


CMF C27 H23 F5 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862504-92-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2,2-dimethylpropyl)-5-[2-[2-fluoro-6-(trifluoromethyl)phenyl]-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862504-91-4


CMF C27 H24 F4 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862504-95-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-cyclopropyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862504-94-7


CMF C23 H25 F N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862504-98-1 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862504-97-0  
 CMF C26 H23 F3 N6



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 862505-01-9 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-00-8  
 CMF C24 H29 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-03-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-02-0


CMF C23 H25 F N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862505-06-4 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862505-05-3  
 CMF C24 H28 F2 N6



CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 862505-08-6 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-07-5  
 CMF C25 H31 F N6


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 862505-11-1 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-10-0

CMF C27 H25 F3 N6


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-14-4 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(4-fluorophenyl)-2-[2-fluoro-6-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-13-3  
 CMF C28 H25 F5 N6

Absolute stereochemistry.



CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 862505-16-6 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-15-5  
 CMF C25 H19 Cl2 F N6






CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-18-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-17-7


CMF C25 H19 F3 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-20-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-19-9


CMF C26 H23 Cl2 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-23-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-22-4


CMF C26 H24 Cl F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-26-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-25-7


CMF C25 H20 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-28-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-27-9


CMF C25 H20 Cl2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-30-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(2,6-difluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-29-1

CMF C26 H22 F4 N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 862505-32-6 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862505-31-5  
CMF C20 H21 F N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 862505-35-9 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[5-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-34-8  
CMF C20 H21 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-37-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(4-fluorophenyl)-1-[2-(4-morpholinyl)ethyl]-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-36-0


CMF C25 H30 F N7 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-39-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(4-fluorophenyl)-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-38-2


CMF C19 H19 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-41-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[1-(1-methylethyl)-3-phenyl-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-40-6


CMF C22 H26 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-44-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-(1-methyl-3-phenyl-1H-pyrazol-4-yl)-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-43-9


CMF C20 H22 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-47-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2-methylpropyl)-5-(3-phenyl-1H-pyrazol-4-yl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1




CRN 862505-46-2  
CMF C19 H20 N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 862505-49-5 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(2,4-difluorophenyl)-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)


CM 1

CRN 862505-48-4  
CMF C19 H18 F2 N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 862505-51-9 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862505-50-8  
 CMF C25 H22 F2 N6



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 862505-54-2 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-53-1  
 CMF C26 H24 Cl2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-56-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-55-3


CMF C25 H22 Cl2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-59-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-58-6


CMF C25 H21 Cl2 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-61-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-60-0


CMF C25 H20 Cl2 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-63-3 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-[(1R)-1,2,2-trimethylpropyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-62-2  
 CMF C27 H25 Cl F2 N6

Absolute stereochemistry.



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 862505-67-7 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862505-66-6  
 CMF C25 H31 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-70-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-69-9


CMF C27 H25 Cl F N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-73-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-72-4


CMF C27 H25 F2 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-76-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?)  
(CA INDEX NAME)

CM 1

CRN 862505-75-7


CMF C27 H24 F3 N5



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862505-79-1 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-dichlorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862505-78-0  
 CMF C27 H24 Cl2 F N5



CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 862505-82-6 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine, 3-(cyclopropylmethyl)-5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-81-5  
 CMF C26 H21 F2 N5






CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-84-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 3-(cyclopropylmethyl)-5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-83-7


CMF C26 H21 Cl2 N5




CM 2

CRN 75-75-2


CMF C H4 O3 S




RN 862505-87-1 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine, 5-(2-cyclopropyl-4-phenyl-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)  
 CM 1  
 CRN 862505-86-0  
 CMF C24 H27 N5



CM 2  
 CRN 75-75-2  
 CMF C H4 O3 S




RN 862505-89-3 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)  
 CM 1  
 CRN 862505-88-2  
 CMF C27 H25 Cl2 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-91-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-90-6


CMF C26 H23 Cl F N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-93-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-(2-cyclopropyl-4-phenyl-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-92-8


CMF C23 H25 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-95-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862505-94-0


CMF C25 H21 F2 N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862505-98-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-pyrazol-4-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)


CM 1

CRN 862505-97-3  
CMF C22 H25 F N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 862506-00-1 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)


CM 1

CRN 862505-99-5  
CMF C23 H28 N6



CM 2

CRN 75-75-2  
CMF C H4 O3 S




RN 862506-03-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-02-3


CMF C25 H22 Cl F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-05-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-(2-cyclopropyl-4-phenyl-1H-imidazol-5-yl)-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-04-5

CMF C22 H24 N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 862506-07-8 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-[2-fluoro-6-(trifluoromethyl)phenyl]-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-06-7  
CMF C26 H22 F4 N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 862506-09-0 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-08-9  
CMF C25 H21 Cl F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-12-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1-methylethyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862506-11-4


CMF C22 H26 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S






RN 862506-15-8 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-[2-fluoro-6-(trifluoromethyl)phenyl]-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-14-7  
CMF C26 H20 F6 N6



CM 2


CRN 75-75-2  
CMF C H4 O3 S



RN 862506-17-0 CAPLUS  
CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-16-9  
CMF C23 H26 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-19-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1-methylethyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?)  
(CA INDEX NAME)

CM 1

CRN 862506-18-1


CMF C22 H24 F2 N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-21-6 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-20-5  
 CMF C25 H20 Cl F3 N6



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 862506-23-8 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-cyclopropyl-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-22-7  
 CMF C22 H22 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-26-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-cyclopropyl-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862506-25-0


CMF C22 H23 F N6



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-28-3 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)


CM 1

CRN 862506-27-2  
 CMF C23 H27 F N6




CM 2

CRN 75-75-2  
 CMF C H4 O3 S




RN 862506-31-8 CAPLUS  
 CN Methanimidamide, N'-[5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-3H-imidazo[4,5-b]pyridin-2-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 862506-33-0 CAPLUS

CN Methanimidamide, N'-[5-[2-(2,6-dichlorophenyl)-1-methyl-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-3H-imidazo[4,5-b]pyridin-2-yl]-N,N-dimethyl- (CA INDEX NAME)




RN 862506-35-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-1-methyl-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 862506-37-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-1-methyl-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862506-40-9 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2,2-dimethylpropyl)-5-(4-phenyl-1H-1,2,3-triazol-5-yl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-39-6


CMF C19 H21 N7



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-43-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(2,2-dimethylpropyl)-5-[4-(4-fluorophenyl)-1H-1,2,3-triazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-42-1


CMF C19 H20 F N7



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-46-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-[4-(4-fluorophenyl)-1H-1,2,3-triazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-45-4


CMF C18 H16 F N7



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-49-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-(cyclopropylmethyl)-5-(4-phenyl-1H-1,2,3-triazol-5-yl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-48-7

CMF C18 H17 N7




CM 2

CRN 75-75-2

CMF C H4 O3 S






RN 862506-51-2 CAPLUS  
 CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-50-1  
 CMF C24 H20 Cl F N6



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 862506-54-5 CAPLUS  
 CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-53-4  
 CMF C24 H20 Cl2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-56-7 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 5-[2-(2,6-dichlorophenyl)-4-(2,4-difluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-55-6


CMF C24 H18 Cl2 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-59-0 CAPLUS

CN 3H-1,2,3-Triazolo[4,5-b]pyridine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-58-9


CMF C22 H25 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-61-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,  
2-amino-5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-N,N-dimethyl-,  
methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-60-3


CMF C21 H25 N7 O2 S



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-64-7 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,  
 2-amino-5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-N,N-  
 dimethyl-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-63-6  
 CMF C23 H19 Cl F N7 O2 S



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 862506-66-9 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,  
 2-amino-5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-N,N-dimethyl-  
 , methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-65-8  
 CMF C23 H19 Cl2 N7 O2 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-68-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,  
2-amino-5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-  
N,N-dimethyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-67-0


CMF C21 H23 F2 N7 O2 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-71-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-70-5


CMF C24 H20 F2 N6 O2 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-73-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-72-7


CMF C25 H22 F2 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-76-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[2-(2-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862506-75-0


CMF C25 H23 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-79-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-78-3


CMF C25 H22 Cl F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-81-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-80-7


CMF C23 H28 N6



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 862506-84-1 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[2-[2-fluoro-6-(trifluoromethyl)phenyl]-4-phenyl-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)



CM 1

CRN 862506-83-0


CMF C26 H22 F4 N6



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 862506-85-2 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,  
2-amino-N,N-dimethyl-5-(5-phenyl-2H-1,2,3-triazol-4-yl)- (CA INDEX NAME)




RN 862506-88-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-[2-fluoro-6-(trifluoromethyl)phenyl]-4-phenyl-1H-imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-87-4


CMF C25 H20 F4 N6 O2 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-91-0 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-phenyl-1H-imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-90-9


CMF C22 H26 N6 O2 S



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862506-94-3 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862506-93-2  
 CMF C24 H20 Cl2 N6 O2 S



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 862506-97-6 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2-chloro-6-fluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-[(1-methylethyl)sulfonyl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862506-96-5  
 CMF C24 H20 Cl F N6 O2 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862506-99-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 3-butyl-5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862506-98-7


CMF C23 H26 F2 N6



CM 2


CRN 75-75-2

CMF C H4 O3 S



RN 862507-01-5 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-5-oxazolyl]-3-(2-methylpropyl)- (CA INDEX NAME)



RN 862507-04-8 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(2,4-difluorophenyl)-2-(1,1-dimethylethyl)-5-oxazolyl]-3-(2-methylpropyl)-, methanesulfonate (1:?)  
 (CA INDEX NAME)


CM 1

CRN 862507-03-7  
 CMF C23 H25 F2 N5 O



CM 2


CRN 75-75-2  
 CMF C H4 O3 S



RN 862507-07-1 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-oxazolyl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1


CRN 862507-06-0  
 CMF C22 H24 F N5 O



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862507-10-6 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-(2-methyl-4-phenyl-5-thiazolyl)-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862507-09-3


CMF C20 H21 N5 S



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 862507-13-9 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[4-(4-fluorophenyl)-2-methyl-5-thiazolyl]-3-(2-methylpropyl)-, methanesulfonate (1:?) (CA INDEX NAME)


CM 1

CRN 862507-12-8  
 CMF C20 H20 F N5 S




CM 2

CRN 75-75-2  
 CMF C H4 O3 S



RN 862507-15-1 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide, 2-amino-5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-5-oxazolyl]-N,N-dimethyl- (CA INDEX NAME)




RN 862507-18-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine-3-sulfonamide,  
2-amino-5-[4-(4-fluorophenyl)-2-(1-methylethyl)-5-oxazolyl]-N,N-dimethyl-,  
methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862507-17-3


CMF C20 H21 F N6 O3 S



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 862507-22-0 CAPLUS


CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 862505-00-8

CMF C24 H29 F N6






CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 862507-23-1 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, methanesulfonate (1:2) (CA INDEX NAME)

CM 1

CRN 862505-00-8


CMF C24 H29 F N6



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 862507-25-3 CAPLUS

CN Butanedioic acid, compd. with 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin-2-amine (1:?) (CA INDEX NAME)

CM 1

CRN 862505-00-8


CMF C24 H29 F N6



CM 2

CRN 110-15-6

CMF C4 H6 O4




RN 862507-27-5 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl]-3-(2,2-dimethylpropyl)-, (2Z)-2-butenedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 862505-00-8

CMF C24 H29 F N6




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 862507-29-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl


RN 862535-99-7 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl-, methanesulfonate (1:?) (CA INDEX NAME)

CM 1

CRN 862535-98-6


CMF C25 H30 F N5



CM 2

CRN 75-75-2

CMF C H4 O3 S




IT 862505-50-8 862505-55-3 862507-99-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of imidazo-pyridine derivs. as inhibitors of p38 kinase)


RN 862505-50-8 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-difluorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862505-55-3 CAPLUS

CN 3H-Imidazo[4,5-b]pyridin-2-amine, 5-[2-(2,6-dichlorophenyl)-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 862507-99-1 CAPLUS

CN Methanimidamide, N'-[5-[2-(2,6-difluorophenyl)-1-methyl-4-phenyl-1H-imidazol-5-yl]-3-(2-methylpropyl)-3H-imidazo[4,5-b]pyridin-2-yl]-N,N-dimethyl- (CA INDEX NAME)



IT 862535-98-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of imidazo-pyridine derivs. as inhibitors of p38 kinase)  
 RN 862535-98-6 CAPLUS  
 CN 3H-Imidazo[4,5-b]pyridine, 5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-2-methyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

24.06

399.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-3.28

-3.28

STN INTERNATIONAL LOGOFF AT 14:26:00 ON 17 APR 2009